BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor

BeiGene on Tuesday announced that it would acquire an exclusive global license to Ensem Therapeutics’ investigational and potentially best-in-class oral CDK2 inhibitor EXT-197, which is being developed for cancer.